Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Petosemtamab - Merus

Next Previous
Drug Profile

Petosemtamab - Merus

Alternative Names: EGFR x LGR5 Biclonics®; Lgr5 x EGFR Biclonics®; MCLA 158

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merus
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase II Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 22 May 2025 Efficacy data from a phase II trial in Squamous cell cancer released by Merus
  • 07 May 2025 Merus seeks accelerated approval from the US FDA for Petosemtamab for Head and neck squamous cell carcinoma
  • 07 May 2025 Merus plans a registrational trial for Head and neck squamous cell carcinoma (HNSCC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top